H1 FY21 performance places us in a strong position for full year FY21 • Revenue $37.2m up 25% on pcp. Growth across all primary categories with 51% of revenue growth coming from emerging technologies and OEM categories 

• Cash on hand at 31 Dec 2020 of $16.8m (2019 : $7.9m) with over $22m of finance facilities available and unutilised.
•  Sales movement by currency to pcp - GBP sales up 5%, USD sales up 92% mainly from increased OEM sales and AUD sales up 16%.
•  C&R revenue increase of 82% from organic growth in emerging technology and OEM sales.
•  EBITDA margin of 32.8% improved from pcp (25.6%) as a result of higher volumes, efficiencies of scale and JobKeeper receipts. Rescheduling of Formula 1 and other race categories from the first half of the 2021 calendar year to the second half.
•  NPAT of $6.6m up 90% on pcp

 Increased dividend

• Fully franked interim dividend of 2.80 cents per share – an increase of 47% on pcp.

Cash flows

•  317% increase in operating cashflow compared to pcp. Due to improved cash conversion ratio, lower working capital and prepaid contractual commitments (some due to timing).
•  Working capital invested decreased by 12% with revenue growth of 25%.
•  EBITDA to cash conversion ratio of 122% for the period (pcp : 68%).
•  Loans drawn down at 30 June 2020 (due to COVID 19 uncertainty) fully repaid during current period.
• Cash on hand at 31 Dec 2020 of $16.8m (2019 : $7.9m) with over $22m of finance facilities available and unutilised.

Presentation

https://www.asx.com.au/asxpdf/20210219/pdf/44stkpvhqf4mml.pdf